It inhibits the binding of CTLA-4 with CD80/CD86, blocks the CTLA-4 pathway, restores the second signal of T cells, increases the number of active effector T cells, and thus enhances the immune attack on tumor cells (33). Here, CTLA4 is linked to neoplasm.